The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
January 23rd 2025
The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.
FDA Approves Avacopan for Treatment of ANCA-Associated Vasculitis
October 8th 2021Avacopan (Tavneos, ChemoCentryx) met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks during a phase 3 trial in patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Read More